MCL Literature Feed

M2-like macrophages secrete IL-1 receptor antagonist (IL-1ra), impairing CAR-T19 function in MCL, suggesting targeting the IL-1 pathway could overcome this novel resistance mechanism.

This phase 1 study shows the novel chemo-free triplet of magrolimab (anti-CD47), obinutuzumab, and venetoclax is a potential strategy for relapsed/refractory B-cell lymphomas, including MCL.

The combination of ibrutinib and venetoclax improves progression-free survival in relapsed/refractory MCL, establishing a highly effective, chemotherapy-free regimen for this difficult-to-treat population.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

In Chinese patients with relapsed/refractory MCL previously treated with a covalent BTKi, the non-covalent BTKi pirtobrutinib achieved a 62.9% overall response rate, confirming its global efficacy.

The Japanese Society of Hematology's 2023 guidelines provide updated, evidence-based recommendations on risk stratification and treatment algorithms for managing mantle cell lymphoma in clinical practice.

This review outlines the evolving MCL treatment paradigm, emphasizing earlier BTKi use, established CAR-T, and emerging non-covalent BTKi and bispecifics for high-risk disease like TP53-mutated MCL.

This review contrasts European and American perspectives on integrating autologous transplant, CAR-T, and allogeneic transplant into MCL treatment, offering clinical guidance in a rapidly evolving therapeutic landscape.

An updated indirect comparison suggests zanubrutinib provides significantly longer progression-free survival than orelabrutinib in relapsed/refractory MCL, informing BTKi choice in the absence of head-to-head trial data.

This review highlights ongoing trials moving CAR-T and bispecific antibodies into earlier lines of MCL therapy, signaling a potential paradigm shift away from traditional chemoimmunotherapy.

The recent FDA approval of Lisocabtagene Maraleucel provides a new CAR-T therapy for relapsed/refractory MCL, offering high response rates but requiring careful management of severe toxicities.

Hemoadsorption with CytoSorb safely reversed severe, refractory cytokine release syndrome in post-CAR-T patients, including one with MCL, offering a potential supportive strategy for managing life-threatening toxicities.

This paper likely characterizes the clinical features, treatment patterns, and poor outcomes of isolated central nervous system relapse in MCL, highlighting a major unmet clinical need.

A phase 1 study in Chinese relapsed/refractory B-cell NHL patients establishes the recommended dose of the HDAC inhibitor abexinostat (80 mg BID) with promising activity, supporting further development.

This myeloma review outlines strategies to overcome proteasome inhibitor resistance by targeting other proteostasis pathways, providing a rationale for exploring similar combinations in relapsed/refractory MCL.

The novel circular RNA-based biomarker, circSCORE, demonstrates prognostic value in relapsed/refractory MCL, offering a new tool for risk stratification in this high-risk patient population.

In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.

In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.

This review summarizes favorable outcomes for CAR-T and bispecific antibodies in relapsed/refractory MCL, detailing their integration into the treatment paradigm for patients with poor prognoses post-BTKi.

This review synthesizes mechanisms of BTKi resistance and highlights next-generation strategies like noncovalent BTKi and PROTACs to overcome this critical challenge in relapsed/refractory MCL.

This review provides a practical guide for clinicians on the approved indications and real-world application of anti-CD19 CAR-T cell therapy for mantle cell lymphoma.

The novel TBL1X inhibitor tegavivint induces DNA damage and synergizes with PARP inhibitors in preclinical MCL models, establishing TBL1X as a new therapeutic target for genomic instability.

The CD20xCD3 bispecific antibody glofitamab induces high and durable complete response rates in heavily pretreated relapsed/refractory MCL, providing a new off-the-shelf immunotherapy option post-BTKi failure.

This correspondence provides expert commentary and clarification on the pivotal trial data for the bispecific antibody glofitamab in patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib monotherapy rapidly resolved bilateral intraocular MCL recurrence presenting as pseudo-uveitis and glaucoma, demonstrating its efficacy in this rare CNS sanctuary site relapse.

Genomic analysis of a single MCL patient identified specific mechanisms of resistance to PD-L1 blockade, providing crucial insights into why checkpoint inhibitors are often ineffective in this lymphoma.

This review summarizes the evolution of BTK inhibitors, highlighting how next-generation agents like pirtobrutinib offer improved selectivity, reduced toxicity, and options to overcome resistance in MCL.

In high-risk, relapsed/refractory MCL, real-world data shows BTKi plus venetoclax is highly effective, with no added survival benefit from an anti-CD20 monoclonal antibody.

This review summarizes the expanding role of T-cell directing immunotherapies, like bispecifics and CAR-T, in treating relapsed/refractory NHL, providing a framework for their application in MCL.

The protein TRIM24 regulates autophagy-mediated resistance to the proteasome inhibitor bortezomib, offering a potential new therapeutic target to overcome drug resistance in relapsed/refractory MCL.